Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WCK 5222 PK Study in Healthy Adults
NCT03630094Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zidebactam in bacterial pneumonia, Gram-negative bacterial infection, complicated urinary tract infection (cUTI) and 1 more, sponsored by Wockhardt. Primary endpoints: Concentrations of cefepime and zidebactam in epithelial lining fluid at Day 3 and Concentrations of cefepime and zidebactam in alveolar macrophage at Day 3. Started Mar 2017; status: completed.
02
Drugs
zidebactam
03
Conditions
bacterial pneumoniaGram-negative bacterial infectioncomplicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT03630094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630094.